Myomo (NYSEAMERICAN:MYO) Insider Harry Kovelman Sells 15,488 Shares

Myomo, Inc. (NYSEAMERICAN:MYO) insider Harry Kovelman sold 15,488 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $1.27, for a total value of $19,669.76. Following the completion of the sale, the insider directly owned 90,245 shares in the company, valued at approximately $114,611.15. This trade represents a 14.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Harry Kovelman also recently made the following trade(s):

• On Thursday, August 20th, Harry Kovelman sold 17,250 shares of Myomo stock. The stock was sold at an average price of $1.73, for a total transaction of $29,842.50.

Myomo Price Performance

NYSEAMERICAN MYO opened at $1.30 on Tuesday. The company has a current ratio of 2.31, a quick ratio of 2.01 and a debt-to-equity ratio of 1.98. The company has a 50-day moving average price of $1.29 and a two-hundred day moving average price of $1.05. The stock has a market cap of $51.49 million, a price-to-earnings ratio of -3.82 and a beta of 1.50. Myomo, Inc. has a 52 week low of $0.60 and a 52 week high of $1.89.

Myomo (NYSEAMERICAN:MYO) last posted its earnings results on Wednesday, August 5th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. The firm had revenue of $11.70 million for the quarter, compared to analysts’ expectations of $10.35 million. Myomo had a negative return on equity of 138.85% and a negative net margin of 33.53%. Analysts forecast that Myomo, Inc. will post -0.32 EPS for the current year.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets raised their target price on Myomo from $9.50 to $10.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Myomo currently has a consensus rating of “Buy” and a consensus price target of $10.00.

Institutional Investors Weigh In On Myomo

A hedge fund recently bought a new stake in Myomo stock. Prescott Group Capital Management L.L.C. purchased a new position in Myomo, Inc. (NYSEAMERICAN:MYO) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 185,433 shares of the company’s stock, valued at approximately $169,000. Prescott Group Capital Management L.L.C. owned approximately 0.48% of Myomo at the end of the most recent reporting period. Institutional investors own 44.99% of the company’s stock.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.